Triad Radiology Associates PLLC, Winston-Salem, North Carolina, USA.
Hackensack University Medical Center, Hackensack, New Jersey, USA.
J Neurointerv Surg. 2018 Dec;10(12):1224-1228. doi: 10.1136/neurintsurg-2018-013910. Epub 2018 Jul 4.
The Medicare and CHIP Reauthorization Act of 2015 remains the payment policy law of the land. 2017 was the first year in which performance reporting will tangibly impact future physician payments. The Centers for Medicare & Medicaid Services (CMS) considers 2017 and 2018 transitional years before full implementation in 2019. As such, 2018 increases the reporting requirements over 2017 in the form of a gradual phase-in while introducing several key changes and new elements. Indeed, it is the nature of the transition itself that led to the somewhat unique title of this manuscript, i.e., MACRA 2.5. Stakeholder feedback to the CMS regarding the program has ranged widely from the elimination of core components to expanding reporting to non-government payers. This article explores the potential impact on neurointerventional physicians.
2015 年《医疗保险和儿童健康保险计划再授权法案》仍是现行支付政策法规。2017 年是绩效报告开始切实影响未来医生薪酬的第一年。医疗保险和医疗补助服务中心(CMS)将 2017 年和 2018 年视为全面实施 2019 年计划之前的过渡期。因此,2018 年通过逐步引入几项关键变化和新元素,增加了比 2017 年更多的报告要求。实际上,正是这种转变本身的性质导致了本文标题有些独特,即 MACRA 2.5。利益相关者向 CMS 提供的有关该计划的反馈意见范围广泛,从取消核心内容到向非政府支付者扩大报告范围。本文探讨了其对神经介入医师的潜在影响。